PHARMIX
ActiveSummary
The computed 12-month bankruptcy probability of PHARMIX is 1.5% (moderate). The 2025 annual accounts show negative equity (-€348,800) and a net result of -€475,283. Equity is shrinking by about 33% per year across the filed financial years. Its solvency ranks better than 6% of 9,624 sector peers (NACE 46, financial year 2025). The company has been active since 1981 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
31-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Weakest financial yearnet -€475,283
Net result drops to -€475,283, the lowest in the series.
10-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
31-12
Financial
Back to profitnet €274,428
Net result €274,428 after 2 loss-making years.
31-12
Financial
Equity above €100,000equity €126,648 ▲143%
Equity rises from €52,220 to €126,648.
22-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
15-05
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
30-05
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
17-08
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format · 17 days late
2020
22-09
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format · 53 days late
2019
27-08
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format · 27 days late
2018
22-08
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format · 22 days late
2017
26-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 44 annual accounts filed, the latest 10 are here; all 44 are under Financials.
0 of 6 deeds read
About the unread acts
We know of 6 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.